Anti-Migraine Drugs Market Size, Share & Trends Analysis Report Forecast 2024-2031


Posted December 16, 2024 by Tan8121

anti-migraine drugs market is anticipated to grow at a significant CAGR during the forecast period (2024-2031).

 
anti-migraine drugs market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). The market growth is mainly attributed to the rising cases of migraine across the globe coupled with growing clinical trials for anti-migraine drugs. According to the Migraine Research Foundation, migraine is the 3rd largest prevalent disease across the globe. In 2018, more than 1 billion people were suffering from migraine. As per the same source, migraine is most prevalent between the age of 18 and 44 and mostly occurred in women more than men. Further, in 2018, there were around 39 million cases of migraine in the US alone. This further provides a boost to the global anti-migraine drugs market.

Get Sample Copy of this Report at

https://www.omrglobal.com/request-sample/anti-migraine-drugs-market

Some key players operating in the market include Eli Lilly & Co., Abbott Laboratories, and Allergan plc, among others. These players are eyeing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships and collaborations, new product launches and development in the existing product portfolio, and so on. Further, pipeline clinical trials by various pharmaceutical companies such as Amgen Inc., and Allergen plc, among others further provide ample opportunity to the market growth. For instance, in March 2019 Axsome Therapeutics, Inc. started the phase III clinical trial for drugs AXS-07, Meloxicam, Rizatriptan, and Placebo for the treatment of acute migraine. AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults. Such activities are further projected to offer substantial growth opportunities to the global anti-migraine drugs market during the forecast period.

Inquire for Discount on this Report at

https://www.omrglobal.com/report-customization/anti-migraine-drugs-market

Market Coverage

The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-

By Type
By Application
Regions covered-

North America
Europe
Asia-Pacific
Rest of the World
Competitive Landscape: Eli Lilly & Co., Abbott Laboratories, and Allergan plc, among others.

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?
How are players addressing challenges to sustain growth?
Where is the investment opportunity?
Global Anti-Migraine Drugs Market Report by Segment

By Type

Triptans
Ergots
Others


By Application

Men
Women



About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: [email protected]

Contact no: +91 780-304-0404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By tanveer
Phone 06267108121
Business Address india
Company name: Orion Market Research
Country India
Categories Advertising , Blogging
Tags business , market , research
Last Updated December 16, 2024